Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins as Strategic Adviser for DCVax Cancer Vaccine Development

Key Takeaways

• Dr. Annalisa Jenkins joins Northwest Biotherapeutics as Strategic Adviser with over 25 years of biopharma leadership experience
• Appointment aims to accelerate development of DCVax personalized dendritic cell cancer vaccines for solid tumors
• Jenkins brings FDA Science Board experience and global R&D expertise from major pharmaceutical companies

---

BETHESDA, Md. — Northwest Biotherapeutics, Inc. (OTCQB: NWBO) announced the strategic appointment of Dr. Annalisa Jenkins, M.B.B.S., F.R.C.P., as Strategic Adviser to advance its DCVax dendritic cell cancer vaccine platform.

Executive Leadership Enhancement

Dr. Jenkins brings more than 25 years of biopharmaceutical leadership spanning global research and development executive roles at major pharmaceutical companies, biotech CEO positions, and membership on the U.S. FDA Science Board. Her appointment represents a significant strategic move for Northwest Biotherapeutics as the company continues developing personalized immune therapies for solid tumor cancers.

DCVax Platform Advancement

The DCVax platform represents a personalized immunotherapy approach using dendritic cells to stimulate the patient’s immune system against cancer. This technology focuses on solid tumor cancers, offering a targeted treatment strategy that leverages the body’s natural immune response mechanisms.

Market Impact and Strategic Direction

Jenkins’ extensive regulatory and commercial experience positions Northwest Biotherapeutics to navigate complex development pathways more effectively. Her FDA Science Board background provides valuable insight into regulatory expectations for innovative cancer treatments, potentially accelerating the DCVax development timeline.

The appointment comes as the immunotherapy market continues expanding, with dendritic cell vaccines representing a promising frontier in personalized cancer treatment. Northwest Biotherapeutics’ focus on solid tumors addresses a significant unmet medical need where traditional treatments often show limited efficacy.

Industry Implications

This strategic advisory appointment signals Northwest Biotherapeutics’ commitment to advancing its dendritic cell vaccine technology through experienced leadership. Jenkins’ track record in global pharmaceutical development could prove instrumental in positioning DCVax for future regulatory submissions and potential commercialization.

The company’s continued investment in high-level strategic advisers demonstrates confidence in the DCVax platform’s potential to address challenging solid tumor cancers through personalized immunotherapy approaches.

---

Frequently Asked Questions

What is DCVax and how does it work?

DCVax is a personalized dendritic cell cancer vaccine that uses the patient’s own immune cells to target solid tumors, training the immune system to recognize and attack cancer cells.

When will DCVax be available to patients?

DCVax is currently in development. The appointment of Dr. Jenkins as Strategic Adviser aims to accelerate the development process, though no specific timeline has been announced.

What makes Dr. Jenkins qualified for this role?

Dr. Jenkins has over 25 years of biopharmaceutical leadership experience, including global R&D roles at major pharmaceutical companies, biotech CEO positions, and FDA Science Board membership.